Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q2 2025 · 10-Q
Revenue$345.51M$345.51M+8.6% vs Q2 2024 Net Income$33.83M$33.83M+35.8% vs Q2 2024 EPS Diluted$0.66$0.66+37.5% vs Q2 2024 Gross Profit$187,437,000+9.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$48,823,000−50.7% Free Cash Flowderived$39,390,000−56.2% Margins · derivedGross margin54.2%+0.7 pt vs Q2 2024
Operating margin15.0%+3.9 pt vs Q2 2024
Net margin9.8%+2.0 pt vs Q2 2024
ended Sep 28, 2024 · filed Nov 7, 2024 · 40 d after period end